


PRODUCT INFORMATION



Satraplatin

Item No. 20537

CAS Registry No.: 129580-63-8
Formal Name: (OC-6-43)-bis(acetato-κO) amminedichloro(cyclohexanamine)-platinum
Synonyms: BMS-182751, BMY 45594, JM 216
MF: C₁₀H₂₂Cl₂N₂O₄Pt
FW: 500.3
Purity: ≥98%
UV/Vis.: λ_{max}: 211 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Satraplatin is supplied as a crystalline solid. A stock solution may be made by dissolving the satraplatin in the solvent of choice, which should be purged with an inert gas. Satraplatin is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of satraplatin in these solvents is approximately 0.5 and 0.16 mg/ml, respectively.

Description

Satraplatin is an orally available antineoplastic platinum(IV) complex.¹ It is more hydrophobic than cisplatin (Item No. 13119) or oxaliplatin (Item No. 13106), which reduces transport-determined acquired resistance.¹ Satraplatin also displays less neurotoxicity in rats than cisplatin or tetraplatin.² Satraplatin has a favorable toxicity profile and appears to have clinical activity against a variety of malignancies.³

References

1. Kelland, L.R., Abel, G., McKeage, M.J., *et al.* Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): An orally active platinum drug. *Cancer Res.* **53(11)**, 2581-2586 (1993).
2. McKeage, M.J., Boxall, F.E., Jones, M., *et al.* Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexylamine-platinum(IV) in comparison to cisplatin and tetraplatin in the rat. *Cancer Res.* **54(3)**, 629-631 (1994).
3. Bhargava, A., and Vaishampayan, U.N. Satraplatin: Leading the new generation of oral platinum agents *Expert. Opin. Investig. Drugs* **18(11)**, 1787-1797 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/29/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM